A multicenter, prospective, open, cohort study on the efficacy and safety of integrated traditional Chinese and Western medicine in the treatment of chronic kidney disease stage 3-4
- Conditions
- chronic kidney disease stage 3-4
- Registration Number
- ITMCTR2200006493
- Lead Sponsor
- the First Affiliated Hospital of Anhui University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
? Age 18 ~ 70 years old, ? meet the diagnostic criteria of CKD stage 3-4; ? Blood pressure < 140/90mmhg, blood potassium < 5.5mmol/l, hemoglobin = 80g/l, infection was controlled, and the condition was stable for more than 2 weeks; ? Those who did not use Chinese patent medicine for CKD within 2 weeks before enrollment, or who had used Chinese patent medicine but had a 2-week washout period; ? Sign informed consent.
? Pregnant or lactating patients ? unable to cooperate, such as psychotic patients ? complicated with active malignant tumors, infectious diseases, liver cirrhosis decompensation, hematopoietic system and other serious primary diseases; ? There is acute urinary tract obstructive disease, which needs surgical treatment; ? Severe arrhythmia, heart failure, NYHA grade III or above, or myocardial infarction or cerebrovascular events within 3 months before enrollment; ? Using corticosteroids, non steroidal anti-inflammatory drugs or immunosuppressants; ? Accord with the clinical or pathological diagnosis of diabetes kidney disease; ? Patients are unwilling to participate and refuse to sign informed consent; ? Patients who are participating in other clinical trials
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EGFR decrease > 40%;Need renal replacement therapy, or enter CKD stage 5;
- Secondary Outcome Measures
Name Time Method Quality of life survey;Mineral and bone metabolism indicators;Cardiovascular events;